image
CRISPR Therapeutics AG CRSP
Healthcare - Biotechnology - NASDAQ - CH
Watchlist
$ 52.17
0.968 %
$ 4.51 B
Market Cap
-11.62
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one CRSP stock under the worst case scenario is HIDDEN Compared to the current market price of 52.2 USD, CRISPR Therapeutics AG is HIDDEN

CRSP Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one CRSP stock under the base case scenario is HIDDEN Compared to the current market price of 52.2 USD, CRISPR Therapeutics AG is HIDDEN

CRSP Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one CRSP stock under the best case scenario is HIDDEN Compared to the current market price of 52.2 USD, CRISPR Therapeutics AG is HIDDEN

CRSP Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart CRSP

image
1M 26%
6M 24%
1Y -11%
3Y -55.0%
5Y -65%
All
$55.0$55.0$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.0$30.0$30.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
35 M REVENUE
-90.57%
Growth Rates
1Year -90.57%
3Years -66.28%
5Years -34.47%
7Years -2.23%
10Years 0.00%
-467 M OPERATING INCOME
-109.66%
Growth Rates
1Year -109.66%
3Years -31.02%
5Years -61.49%
7Years -32.62%
10Years -53.02%
-366 M NET INCOME
-138.43%
Growth Rates
1Year -138.43%
3Years -25.35%
5Years -45.31%
7Years -27.10%
10Years -48.98%
-143 M OPERATING CASH FLOW
45.17%
Growth Rates
1Year 45.17%
3Years -8.15%
5Years -28.61%
7Years -10.70%
10Years -40.41%
-280 M INVESTING CASH FLOW
-74.87%
Growth Rates
1Year -74.87%
3Years 35.30%
5Years -192.11%
7Years -65.31%
10Years 0.00%
332 M FINANCING CASH FLOW
429.78%
Growth Rates
1Year 429.78%
3Years 9.78%
5Years -5.09%
7Years 99.84%
10Years 51.76%
865 K REVENUE
-97.53%
Growth Rates
1Year -90.57%
3Years -66.28%
5Years -34.47%
7Years -2.23%
10Years 0.00%
-148 M OPERATING INCOME
-129.80%
Growth Rates
1Year -109.66%
3Years -31.02%
5Years -61.49%
7Years -32.62%
10Years -53.02%
-136 M NET INCOME
-264.49%
Growth Rates
1Year -138.43%
3Years -25.35%
5Years -45.31%
7Years -27.10%
10Years -48.98%
-53.9 M OPERATING CASH FLOW
-7.83%
Growth Rates
1Year 45.17%
3Years -8.15%
5Years -28.61%
7Years -10.70%
10Years -40.41%
-19.8 M INVESTING CASH FLOW
-18.67%
Growth Rates
1Year -74.87%
3Years 35.30%
5Years -192.11%
7Years -65.31%
10Years 0.00%
10.6 M FINANCING CASH FLOW
-37.26%
Growth Rates
1Year 429.78%
3Years 9.78%
5Years -5.09%
7Years 99.84%
10Years 51.76%
Balance Sheet CRISPR Therapeutics AG
image
Current Assets 1.94 B
Cash & Short-Term Investments 1.9 B
Receivables 25 M
Other Current Assets 8.31 M
Non-Current Assets 305 M
Long-Term Investments 0
PP&E 278 M
Other Non-Current Assets 27.3 M
84.92 %12.38 %Total Assets$2.2b
Current Liabilities 87.8 M
Accounts Payable 14.7 M
Short-Term Debt 17.3 M
Other Current Liabilities 55.8 M
Non-Current Liabilities 222 M
Long-Term Debt 206 M
Other Non-Current Liabilities 15.8 M
4.75 %5.58 %18.00 %66.59 %5.09 %Total Liabilities$310.0m
EFFICIENCY
Earnings Waterfall CRISPR Therapeutics AG
image
Revenue 35 M
Cost Of Revenue 110 M
Gross Profit -75.2 M
Operating Expenses 504 M
Operating Income -467 M
Other Expenses -100 M
Net Income -366 M
100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)(600m)(600m)35m(110m)(75m)(504m)(467m)100m(366m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
-215.00% GROSS MARGIN
-215.00%
Averages
1Year -215.00%
3Years -8445.60%
5Years -14950.66%
7Years -11179.59%
10Years -8403.56%
-1333.05% OPERATING MARGIN
-1333.05%
Averages
1Year -1333.05%
3Years -51929.24%
5Years -44204.06%
7Years -32298.85%
10Years -23798.56%
-1046.43% NET MARGIN
-1046.43%
Averages
1Year -1046.43%
3Years -50070.17%
5Years -42883.37%
7Years -31382.12%
10Years -23074.76%
-18.96% ROE
-18.96%
Averages
1Year -18.96%
3Years -20.59%
5Years -13.40%
7Years -14.56%
10Years -5.95%
-16.34% ROA
-16.34%
Averages
1Year -16.34%
3Years -17.40%
5Years -11.51%
7Years -12.15%
10Years -13.32%
-21.70% ROIC
-21.70%
Averages
1Year -21.70%
3Years -21.14%
5Years -13.93%
7Years -14.24%
10Years -16.43%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis CRISPR Therapeutics AG
image
500m500m400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)(600m)(600m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -366 M
Depreciation & Amortization 19.3 M
Capital Expenditures -1.9 M
Stock-Based Compensation 86.6 M
Change in Working Capital 156 M
Others -57.3 M
Free Cash Flow -145 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets CRISPR Therapeutics AG
image
Wall Street analysts predict an average 1-year price target for CRSP of $75.7 , with forecasts ranging from a low of $59 to a high of $100 .
CRSP Lowest Price Target Wall Street Target
59 USD 13.09%
CRSP Average Price Target Wall Street Target
75.7 USD 45.13%
CRSP Highest Price Target Wall Street Target
100 USD 91.68%
Price
Max Price Target
Min Price Target
Average Price Target
1001009090808070706060505040403030Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership CRISPR Therapeutics AG
image
Sold
0-3 MONTHS
141 K USD 1
3-6 MONTHS
4.37 M USD 4
6-9 MONTHS
2.74 M USD 2
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
314 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
2 Beaten-Down Stocks With Massive Upside Potential There are many promising corporations that investors can buy on a dip due to recent market volatility or company-specific issues that predate this year. Take, for instance, CRISPR Therapeutics (CRSP 6.43%) and Viking Therapeutics (VKTX 3.94%), two mid-cap biotech companies that have lagged broader equities over the trailing-12-month period. fool.com - 1 week ago
2 Growth Stocks to Buy Hand Over Fist in July July kicks off the latter half of 2025, and the first six months of this year have been eventful, to say the least. fool.com - 1 week ago
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. zacks.com - 1 week ago
Is CRISPR Therapeutics (CRSP) a Buy as Wall Street Analysts Look Optimistic? When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? zacks.com - 2 weeks ago
CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline -New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% in LDL, with a well-tolerated safety profile- globenewswire.com - 2 weeks ago
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains. zacks.com - 2 weeks ago
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $46.78, marking a +2.7% move from the previous day. zacks.com - 2 weeks ago
The Best Stocks to Invest $1,000 in Right Now Is it time to reload your portfolio with some new picks? That's easier said than done right now. fool.com - 2 weeks ago
The Big 3: CRSP, OKLO, GME Mike Shorr (@ProsperTradingAcademy) looks to manage risk levels in his 3 example options trades. For Crispr Therapeutics (CRSP), he's looking at low-implied volatility in the gene-editing biotech company. youtube.com - 2 weeks ago
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. fool.com - 2 weeks ago
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics? CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded field. zacks.com - 3 weeks ago
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $44.43, representing a +2.87% change from its previous close. zacks.com - 3 weeks ago
8. Profile Summary

CRISPR Therapeutics AG CRSP

image
COUNTRY CH
INDUSTRY Biotechnology
MARKET CAP $ 4.51 B
Dividend Yield 0.00%
Description CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Contact Baarerstrasse 14, Zug, 6300 https://www.crisprtx.com
IPO Date Oct. 19, 2016
Employees 393
Officers Dr. Daniel G. Anderson Ph.D. Scientific Founder & Advisory Board Member Dr. Matthew Porteus M.D., Ph.D. Scientific Founder & Advisory Board Member Dr. Craig C. Mello Ph.D. Scientific Founder & Advisory Board Member Dr. Raju Yashaswi Prasad Ph.D. Chief Financial Officer Dr. Samarth Kulkarni Ph.D. Chief Executive Officer & Chairman Mr. James R. Kasinger J.D. General Counsel & Secretary Dr. Naimish Patel C.M., M.D. Chief Medical Officer Mr. Shaun Foy CFA Founder Dr. Emmanuelle Marie Charpentier Ph.D. Co-Founder & Scientific Advisory Board Member Dr. Chad A. Cowan Ph.D. Scientific Founder